We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Feb 2023 - 18 Feb 2023

Novel Hydrocephalus Valve Addresses Postural Changes

By HospiMedica International staff writers
Posted on 28 May 2020
Print article
Image: The M.blue adjustable gravitational valve with integrated fixed pressure differential valve (Photo courtesy of Aesculap)
Image: The M.blue adjustable gravitational valve with integrated fixed pressure differential valve (Photo courtesy of Aesculap)
New valve technology integrates gravitational technology with a fixed differential pressure unit into one valve, allowing for a simple, position-dependent hydrocephalus solution.

The Aesculap (Tuttlingen, Germany) M.blue valve is an adjustable gravitational valve with an integrated fixed pressure differential valve that together provide automatic adjustment of the opening pressure during the most active time of the day, when people are standing and moving about; the integration of the fixed pressure differential valve not only addresses the posture changes, and also counteracts the risk of possible over-drainage complications, especially in the upright and active body position.

The differential pressure unit is available in 0,5,10 and 15 cm H20, and is effective in all body positions. When lying down, the differential pressure unit acts alone. If the brain pressure rises above the selected opening pressure, a microspiral spring is activated to drain cerebrospinal fluid (CSF). The gravitational unit in the M.blue valve is adjustable from 0-40 cm H20 and is only activated in an upright body position. The combination of both units, gravitational and differential pressure unit, determines the total opening pressure of the M.blue valve.

Design feature include a durable, highly bio-compatible titanium shell, oxidized to display a shade of blue, and a soft touch mechanism that allows for comfortable adjustment. An active-lock mechanism protects it from unintentional reprogramming, not only after a magnetic resonance imaging (MRI) scan, but also from everyday magnets such as smartphones, tablets device, headphones, and hearing devices. For more challenging forms of hydrocephalus, the M.blue plus valve provides an adjustable differential pressure unit (the proGAV 2.0) to provide a customizable solution.

“The patient is our priority and we will continue to invest in research and development to create better solutions,” said Christoph Miethke, CEO and founder of MIETHKE (Potsdam, Germany), the manufacturer of the M.blue hydrocephalus valves for Aesculap. “Our focus on Hydrocephalus valves creates an expertise and openness to future developments that allows us to serve in a way that will improve the lives that we touch.”

“We are very pleased to be able to continue to provide healthcare teams with new and innovative solutions,” said Chuck DiNardo, President of Aesculap. “With our strong partnership with MIETHKE comes an impactful collaborative effort to bring better Hydrocephalus solutions to patients, such as the new M.blue valve.”

Hydrocephalus is a condition in which an excess of CSF accumulates within the ventricles and increases intracranial pressure (ICP) in the brain, resulting in a life-threatening situation. The challenge is to regulate CSF drainage to keep within normal physiological ranges. CSF tends to drain faster when a patient is standing, causing a decrease in ICP, which results in headaches, nausea and other debilitating symptoms. This necessitates the need for higher valve resistance in upright positions; the taller the patient, the higher the necessary resistance.

Related Links:
Aesculap
MIETHKE


Gold Supplier
Ultrasound Transducer/Probe Cleaner
Transeptic Cleaning Solution
New
Mechanical Ventilator
NKV-550 Series
New
Surgical Light
HyLED 600 Series
New
Endoscopy Display
EndoVue Plus 24”

Print article

Channels

AI

view channel
Image: A novel research study moves the needle on predicting coronary artery disease (Photo courtesy of Pexels)

AI-Enabled ECG Analysis Predicts Heart Attack Risk Nearly as well as CT Scans

Increased coronary artery calcium is a marker of coronary artery disease that can lead to a heart attack. Traditionally, CT scans are used to diagnose buildup of coronary artery calcium, although CT scanners... Read more

Critical Care

view channel
Image: The new biomaterial heals tissues from the inside out (Photo courtesy of UC San Diego)

Groundbreaking Biomaterial Injected Intravenously Repairs Cells and Tissue Damaged by Heart Attack and TBI

Following a heart attack, there is development of scar tissue, which affects muscle function and can result in congestive heart failure. However, there is still no established treatment available for repairing... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.